Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bradykinin antagonists: present progress and future prospects.

J M Stewart1, L Gera, E J York

  • 1Department of Biochemistry and Molecular Genetics, University of Colorado Medical School, Denver 80262, USA. john.stewart@uchsc.edu

Immunopharmacology
|December 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating compliance with the care standard of proactively assessing bone health in patients with diabetes: a pilot audit of practice across Asia by the Asia Pacific Consortium on Osteoporosis (APCO).

Archives of osteoporosis·2024
Same author

Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2016
Same author

Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes.

Diabetes, obesity & metabolism·2015
Same author

Association between skeletal muscle fat content and very-low-density lipoprotein-apolipoprotein B-100 transport in obesity: effect of weight loss.

Diabetes, obesity & metabolism·2014
Same author

Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.

Diabetes, obesity & metabolism·2013
Same journal

Papers of the 15th International Conference on Kinins. Part III. Nara, Japan, 19-24 October 1998.

Immunopharmacology·2001
Same journal

Papers from the 15th International Conference on Kinins. Part II. Nara, Japan, 19-24 October 1998.

Immunopharmacology·2001
Same journal

Interleukin 2 maintains biologic stability and sterility over prolonged time.

Immunopharmacology·2000
Same journal

Comparative study of lymphocyte-suppressive potency between prednisolone and methylprednisolone in rheumatoid arthritis.

Immunopharmacology·2000
Same journal

Activation of rat splenic macrophage and lymphocyte functions by fumonisin B1.

Immunopharmacology·2000
Same journal

Sublytic complement attack reduces infarct size in rabbit isolated hearts: evidence for C5a-mediated cardioprotection.

Immunopharmacology·2000
See all related articles

Bradykinin (BK) antagonists are valuable research tools and drug candidates for inflammation and cancer. The best peptide antagonist is orally available, stable, and effective against cancers in vivo.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Oncology

Background:

  • Bradykinin (BK) antagonists are crucial for understanding kinin roles in physiology and disease.
  • Peptide antagonists targeting BK B1 or B2 receptors, or both, are currently available.
  • Non-peptide BK B2 antagonists are emerging as investigational drugs.

Purpose of the Study:

  • To review the development and applications of bradykinin antagonist peptides.
  • To highlight the potential of BK antagonists in treating inflammatory conditions and cancers.
  • To discuss the characteristics and efficacy of advanced BK antagonists.

Main Methods:

  • Review of existing literature on bradykinin antagonists.
  • Analysis of peptide and non-peptide antagonist specificities and potencies.

Related Experiment Videos

  • Evaluation of in vitro and in vivo data for cancer activity.

    • Main Results:

    • Potent peptide antagonists exist for BK B1, B2, or both receptors.
    • A superior peptide B1-B2 antagonist demonstrates stability, oral availability, and long in vivo half-life.
    • Certain dimers and smaller molecules of this antagonist show activity against various cancers.

    Conclusions:

    • Bradykinin antagonist peptides are effective tools in physiological and pathological research.
    • Advanced peptide antagonists offer therapeutic promise for inflammatory diseases and cancers.
    • Further investigation into BK antagonist dimers and small molecules may yield novel cancer treatments.